<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25628205</article-id>
      <article-id pub-id-type="pmc">4879920</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082014RC2794</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082014RC2794</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cystectomy with orthotopic ileal neobladder reconstruction for treatment of bladder contracture after intravesical bacillus Calmette-Guerin therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Vetorazzo</surname>
            <given-names>Jos&#xE9; Eduardo</given-names>
            <suffix>Filho</suffix>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bahia</surname>
            <given-names>Leandro Augusto Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vedovato</surname>
            <given-names>Bruno C&#xE9;sar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maron</surname>
            <given-names>Paulo Eduardo Goulart</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Esteves</surname>
            <given-names>Paulo Ebert</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Roni de Carvalho</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perez</surname>
            <given-names>Marjo Deninson Cardenuto</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Irmandade da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <author-notes>
        <corresp> Corresponding author: Jos&#xE9; Eduardo Vetorazzo Filho &#x2212; Rua Doutor Ces&#xE1;rio Mota J&#xFA;nior, 112 &#x2013; Vila Buarque &#x2013; Zip code: 01221-020 &#x2013; S&#xE3;o Paulo, SP, Brazil &#x2212; E-mail: <email>jevetorazzo@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Oct-Dec</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Oct-Dec</season>
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <issue>4</issue>
      <fpage>502</fpage>
      <lpage>504</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>4</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Bladder cancer is an important health problem worldwide due to high prevalence rates and costs related to treatment. A reduction in recurrence rates has been observed since the introduction of adjuvant intravesical immunotherapy with bacillus Calmette-Guerin. There are mild complications that are easily solved by local measures and orientations. Bladder contracture, a rare and severe local complication, in some cases leading to disability, is observed primarily in patients in a maintenance program. In this article we reported the case of a male patient who underwent transurethral resection of the bladder because of a high-grade T1 urothelial carcinoma and developed this complication during treatment with bacillus Calmette-Guerin. For this reason he was submitted to cystoprostatectomy with orthotopic ileal neobladder reconstruction.</p>
      </abstract>
      <kwd-group>
        <kwd>Urinary bladder neoplasms</kwd>
        <kwd>BCG vaccine</kwd>
        <kwd>Administration</kwd>
        <kwd>intravesical</kwd>
        <kwd>Cystectomy</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="6"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Bladder cancer is an important health problem worldwide due to high prevalence rates and costs related to treatment.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
According to the <italic>Instituto Nacional de C&#xE2;ncer</italic> (INCA), approximately nine thousand cases were expected to occur in Brazil, in 2012. Out of these cases, 75% to 85% comprise superficial tumors, that is, the disease is confined to the mucosa (Ta-CIS) or submucosa (T1), and these patients are potential candidates for complementing treatment with chemotherapy or immunotherapy.<sup>(<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>)</sup> The recurrence rates have dropped since the adjuvant intravesical immunotherapy with bacillus of Calmette-Gu&#xE9;rin (BCG) was introduced.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
      <p>Although the use of BCG is considered effective, not all individuals benefit from it. Toxicity, diverse complications and no therapeutic response should be considered when proposing this adjuvant therapy.(<xref rid="B2" ref-type="bibr"><sup>2</sup></xref>)
</p>
      <p>The main complications are mild and easily solved by local measures and orientations. Bladder contracture is a rare and severe local complication that leads to disability in some cases, and is observed primarily in patients in a maintenance program.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 53-year-old male smoker patient presented macroscopic hematuria with no pain for three days, in 2009. He went to the Emergency Department of the <italic>Irmandade da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo</italic>, was submitted to ultrasound of the urinary tract that revealed an intravesical mass suggesting neoplasm in the left lateral wall. Transurethral resection (TUR) of the bladder was performed and he was diagnosed as high-grade T1 urothelial carcinoma. Eight weeks later the patient underwent another TUR but he had no recurrence or new lesions. Biopsies of the previously resected bed showed cystitis. He started on adjuvant intravesical therapy with BCG after one month and was treated for three years. According to the protocol of the organization, he was on induction phase for 8 weeks and on maintenance phase for 3 years (one weekly cycle for 3 weeks, at 3 and 6 months; and then every 6 months). In both phases he received an 80-mg dose in each session. In the second year of treatment the patient had no recurrences, and only some lower urinary tract symptoms (LUTS) related to storage, suck as pollakiuria and urgency, with no leakage. However, he felt adjusted to treatment and with no significant deterioration in quality of life. In the beginning of the third and last year of therapy, the urinary symptoms worsened and urinary frequency increased to 20 times a day, urgency with disabling incontinence and suprapubic pain with little bladder filling. In this period, it was necessary to discontinue treatment. Urethrocystography showed a small-capacity bladder, bilateral grade I vesicoureteral reflux and considerable post-micturition residual urine (<xref ref-type="fig" rid="f01">Figure 1</xref>). The urodynamic study demonstrated very low vesical capacity (40ml) with enhanced sensitivity in this volume, besides high detrusor pressure (Pdet=78cmH<sub>2</sub>O), confirming the finding of bladder contracture. Cystoscopy during this period showed no neoplastic lesions. The patient underwent cystoprostatectomy due to incapacitating symptoms, with orthotopic ileal neobladder reconstruction and lymphadenectomy. A small bladder, with no other significant features, was observed during surgery. The procedure went uneventfully. The patient progressed with a urinary fistula in the ileal loop on the 10<sup>th</sup> postoperative day, which resolved with conservative measures. He was discharged from hospital with no further events and followed up at the outpatient clinic for distension of the neobladder, with no complaints (<xref ref-type="fig" rid="f02">Figure 2</xref>). The pathological examination revealed only inflammatory cystitis in the surgical specimen and absence of neoplasms.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Urethrocystography. Small capacity bladder, bilateral grade I vesicoureteral reflux and post-micturition residual urine</title></caption><graphic xlink:href="1679-4508-eins-12-4-0502-gf01"/></fig>
</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Urethrocystography. Neobladder in late postoperative period</title></caption><graphic xlink:href="1679-4508-eins-12-4-0502-gf02"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>BCG is a first line therapy for high-grade Ta/T1 urothelial carcinoma and carcinoma <italic>in situ</italic> after TUR, particularly as maintenance therapy. It showed to be superior to intravesical chemotherapy in delaying tumor progression.<sup>(<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>)</sup> However, it should not be administered immediately after resection; in general, one should wait for two weeks for local healing in order to avoid absorption and hematogenous dissemination of mycobacteria.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
      <p>Although there is no consensus about the ideal dose, six to eight instillations, once a week, followed by three maintenance doses every 3 to 6 months, in the first year, and every six months as from the second year, demonstrated promising results, according to the SWOG protocol, which was used in the present case.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
      <p>Assuming that maintenance therapy is necessary for optimal efficacy, toxicity becomes more relevant.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> It is substantially greater with intensive treatment, but severe secondary effects have been observed after few instillations.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> Storage symptoms (dysuria, pollakiuria and hematuria) are commonly associated side effects that occur usually after the third administration; they result from immune stimulation, with release of lymphokines as an associated inflammatory response.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
      <p>It is recommended to delay new instillations of BCG after several TUR and initiate anti-tuberculosis antibiotics, since they may be useful in cases of continued inflammation or infection.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
      <p>Bladder contracture is an uncommon complication but severe, and occurs in less than 1% of the patients.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> A series updated by Lamm et al. reported bladder contracture in only 5 (0.2%) out of of 2,602 patients evaluated.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup>
</p>
      <p>Nieder et al. identified only two cases of this complication out of 2,255 in two organizations, leading to a rate of 0.05 to 0.3%. In their study, both cases presented intravesical therapy complication as early as in the induction phase. One of these patients had evidence of bladder contracture after the fifth dose. There was probably leakage in the non-healed resection site, which would initiate an extensive perivesical inflammation and a fistula, resulting in bladder contracture.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup>
</p>
      <p>For this reason, such complication should be suspected in patients with intense micturition symptoms in any phase and, primarily in the maintenance phase of BCG immunotherapy.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>)</sup> Some centers currently use prophylactic isoniazid in an attempt to decrease the incidence of contracture but the results vary.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup> The use of associated interferon was also proposed to try to reduce the BCG dose and intolerance, and some series of few patients presented favorable results. The study conducted by Nieder et al.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> described the first case of bladder contracture in a patient on this combined therapy. Conservative treatment can be initially tried with hydrodistension and use of antimuscarinics.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> However, surgery should be considered in patients refractory to treatment or with incapacitating symptoms. Some options, such as bladder augmentation and cystectomy with reconstruction of the ileal conduit, might lead to tumor recurrence and negative effects on quality of life (QoL), respectively.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> Cystoprostatectomy with reconstruction of intestinal neobladder plays it role in improving QoL and being safer as to possible tumor recurrences.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup>
</p>
    </sec>
    <sec sec-type="conclusions">
      <title>CONCLUSION</title>
      <p>Bladder contracture is a rare complication that must be thought of in patients with severe lower urinary tract symptoms and on Bacillus Calmette-Gu&#xE9;rin therapy. When medical therapy is not possible, surgical approach with cystoprostatectomy and neobladder is the best option, for being a definite treatment and providing improved quality of life.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFER&#xCA;NCIAS</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koya</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Soloway</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Complications of intravesical therapy for urothelial cancer of the bladder</article-title>
          <source>J Urol</source>
          <year>2006</year>
          <volume>175</volume>
          <issue>6</issue>
          <fpage>2004</fpage>
          <lpage>2010</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">16697786</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hameed</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sezian</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Thwaini</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Bladder contracture: review for intravesical bacillus Calmette-Guerin complication</article-title>
          <source>Can J Urol</source>
          <year>2007</year>
          <volume>14</volume>
          <issue>6</issue>
          <fpage>3745</fpage>
          <lpage>3749</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">18163926</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>&#x15E;enocak</surname>
              <given-names>&#xC7;a&#x11F;ri</given-names>
            </name>
            <name>
              <surname>Kara</surname>
              <given-names>Cengiz</given-names>
            </name>
            <name>
              <surname>O&#x11F;uz</surname>
              <given-names>Ural</given-names>
            </name>
            <name>
              <surname>&#xDC;nsal</surname>
              <given-names>Ali</given-names>
            </name>
          </person-group>
          <article-title>Hydrodistention and anticholinergics are useful for bladder contracture caused by intravesical bcg therapy: a case report</article-title>
          <source>N J Med</source>
          <year>2011</year>
          <volume>28</volume>
          <issue>3</issue>
          <fpage>185</fpage>
          <lpage>187</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manasia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alcaraz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cetina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alcover</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder</article-title>
          <source>J Urol</source>
          <year>2001</year>
          <volume>165</volume>
          <issue>2</issue>
          <fpage>529</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="pmid">11176420</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lamm</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>van der Meijden</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Morales</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brosman</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Catalona</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Herr</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Soloway</surname>
              <given-names>MS</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer</article-title>
          <source>J Urol</source>
          <year>1992</year>
          <volume>147</volume>
          <issue>3</issue>
          <fpage>596</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="pmid">1538436</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nieder</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Sved</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Skinner</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Soloway</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Gu&#xE9;rin-induced bladder contractures</article-title>
          <source>Urology</source>
          <year>2005</year>
          <volume>65</volume>
          <issue>5</issue>
          <fpage>909</fpage>
          <lpage>912</lpage>
          <pub-id pub-id-type="pmid">15882722</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="TRen" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cistectomia com reconstru&#xE7;&#xE3;o de neobexiga ortot&#xF3;pica ileal para tratamento de bexiga contra&#xED;da ap&#xF3;s aplica&#xE7;&#xE3;o de bacilo de Calmette-Gu&#xE9;rin intravesical</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Vetorazzo</surname>
            <given-names>Jos&#xE9; Eduardo</given-names>
            <suffix>Filho</suffix>
          </name>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bahia</surname>
            <given-names>Leandro Augusto Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vedovato</surname>
            <given-names>Bruno C&#xE9;sar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maron</surname>
            <given-names>Paulo Eduardo Goulart</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Esteves</surname>
            <given-names>Paulo Ebert</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Roni de Carvalho</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perez</surname>
            <given-names>Marjo Deninson Cardenuto</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1002"><label>1</label>Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Irmandade da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <author-notes>
        <corresp> Autor correspondente: Jos&#xE9; Eduardo Vetorazzo Filho &#x2212; Rua Doutor Ces&#xE1;rio Mota J&#xFA;nior, 112 &#x2013; Vila Buarque &#x2212; CEP: 01221-020 &#x2212; S&#xE3;o Paulo, SP, Brasil &#x2212; E-mail: <email>jevetorazzo@gmail.com</email></corresp>
      </author-notes>
      <abstract>
        <p>O c&#xE2;ncer de bexiga &#xE9; um importante problema de sa&#xFA;de mundial, tanto pelas elevadas taxas de preval&#xEA;ncia, quanto pelos custos relacionados ao tratamento. Desde a introdu&#xE7;&#xE3;o da imunoterapia intravesical adjuvante com bacilo Calmette-Gu&#xE9;rin, vem sendo observada diminui&#xE7;&#xE3;o na taxa de recorr&#xEA;ncia. As principais complica&#xE7;&#xF5;es s&#xE3;o de pequeno porte e simples resolu&#xE7;&#xE3;o a partir de medidas locais e orienta&#xE7;&#xF5;es. A bexiga contra&#xED;da, uma complica&#xE7;&#xE3;o local rara e grave, mas incapacitante em alguns casos, &#xE9; observada principalmente em doentes com um programa de manuten&#xE7;&#xE3;o. Relatamos aqui o caso de um paciente masculino submetido a ressec&#xE7;&#xE3;o transuretral da bexiga por um carcinoma urotelial T1 de alto grau, que desenvolveu tal complica&#xE7;&#xE3;o durante tratamento com bacilo Calmette-Gu&#xE9;rin, sendo portanto submetido &#xE0; cistoprostatectomia com realiza&#xE7;&#xE3;o de neobexiga ortot&#xF3;pica ileal.</p>
      </abstract>
      <kwd-group>
        <kwd>Neoplasias da bexiga urin&#xE1;ria</kwd>
        <kwd>Vacina BCG</kwd>
        <kwd>Administra&#xE7;&#xE3;o intravesical</kwd>
        <kwd>Cistectomia</kwd>
        <kwd>Relatos de casos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>INTRODU&#xC7;&#xC3;O</title>
        <p>O c&#xE2;ncer de bexiga &#xE9; um importante problema de sa&#xFA;de mundial, tanto pelas elevadas taxas de preval&#xEA;ncia quanto pelos custos relacionados ao tratamento.<sup>(<xref rid="B1" ref-type="bibr">1</xref>) </sup>Segundo o Instituto Nacional de C&#xE2;ncer (INCA), aproximadamente 9.000 casos eram esperados para o ano de 2012 no Brasil. Desses casos, 75% a 85% s&#xE3;o compostos por tumores superficiais, ou seja, doen&#xE7;a confinada &#xE0; mucosa (Ta-CIS) ou submucosa (T1), tornando esses pacientes potenciais candidatos para realiza&#xE7;&#xE3;o de terapia complementar com quimioterapia ou imunoterapia.<sup>(<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>)</sup> Desde a introdu&#xE7;&#xE3;o da imunoterapia intravesical adjuvante com bacilo de Calmette-Gu&#xE9;rin (BCG), foi observada diminui&#xE7;&#xE3;o na taxa de recorr&#xEA;ncia.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
        <p>Embora o uso de BCG seja considerado muito eficaz, nem todos os casos t&#xEA;m benef&#xED;cio. Toxicidade, complica&#xE7;&#xF5;es das mais variadas e n&#xE3;o resposta terap&#xEA;utica devem ser levados em conta quando se prop&#xF5;e a adjuv&#xE2;ncia.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
        <p>As principais complica&#xE7;&#xF5;es s&#xE3;o de pequeno porte, de resolu&#xE7;&#xE3;o simples a partir de medidas locais e orienta&#xE7;&#xF5;es. A bexiga contra&#xED;da, uma complica&#xE7;&#xE3;o local rara e grave, incapacitante em alguns casos, &#xE9; observada principalmente em doentes com um programa de manuten&#xE7;&#xE3;o.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
      </sec>
      <sec>
        <title>RELATO DE CASO</title>
        <p>Paciente do sexo masculino, 53 anos, tabagista, apresentou hemat&#xFA;ria macrosc&#xF3;pica indolor, de in&#xED;cio h&#xE1; 3 dias, no ano de 2009. Procurou o Pronto-Socorro da Irmandade da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, sendo submetido &#xE0; ultrassonografia do aparelho urin&#xE1;rio, a qual revelou tumora&#xE7;&#xE3;o intravesical sugestiva de neoplasia em parede lateral esquerda. Foi realizada ressec&#xE7;&#xE3;o transuretral (RTU) da bexiga com diagn&#xF3;stico de carcinoma urotelial T1 de alto grau. Ap&#xF3;s 8 semanas, foi submetido a nova RTU, dessa vez sem recidiva ou novas les&#xF5;es. Bi&#xF3;psias do leito ressecado previamente revelaram cistite. Iniciou terapia adjuvante intravesical com BCG ap&#xF3;s 1 m&#xEA;s, com dura&#xE7;&#xE3;o total de 3 anos. Conforme protocolo do servi&#xE7;o, realizou fase de indu&#xE7;&#xE3;o por 8 semanas e de manuten&#xE7;&#xE3;o por 3 anos (1 ciclo semanal por 3 semanas, em 3 e 6 meses; a partir da&#xED;, a cada 6 meses), ambas com dose de 80mg em cada sess&#xE3;o. No segundo ano de tratamento, apresentava-se sem recidivas, com alguns sintomas do trato urin&#xE1;rio inferior relacionados ao armazenamento, como polaci&#xFA;ria e urg&#xEA;ncia miccional sem perdas. Apesar disso, estava adaptado e sem deteriora&#xE7;&#xE3;o significativa da qualidade de vida. No in&#xED;cio do terceiro e &#xFA;ltimo ano, os sintomas urin&#xE1;rios pioraram, dessa vez com aumento da frequ&#xEA;ncia urin&#xE1;ria em torno de 20 vezes ao dia, urg&#xEA;ncia com perdas incapacitante e dor suprap&#xFA;bica ao menor enchimento vesical. Nesse per&#xED;odo, foi necess&#xE1;rio interromper o tratamento. Uretrocistografia revelou bexiga de pequena capacidade, refluxo vesicureteral bilateral grau I e res&#xED;duo p&#xF3;s-miccional consider&#xE1;vel (<xref ref-type="fig" rid="f1002">Figura 1</xref>). Estudo urodin&#xE2;mico evidenciou capacidade vesical muito baixa (40mL) com sensibilidade muito aumentada nesse volume, al&#xE9;m de alta press&#xE3;o detrusora (Pdet=78cmH<sub>2</sub>O), confirmando o achado de bexiga contra&#xED;da. Cistoscopia desse per&#xED;odo n&#xE3;o evidenciou les&#xF5;es neopl&#xE1;sicas. Devido aos sintomas incapacitantes, o paciente foi submetido &#xE0; cistoprostatectomia com realiza&#xE7;&#xE3;o de neobexiga ortot&#xF3;pica ileal e linfadenectomia. No intraoperat&#xF3;rio, foi evidenciada bexiga de pequeno tamanho, sem outras caracter&#xED;sticas. Procedimento sem intercorr&#xEA;ncias. Evoluiu com f&#xED;stula urin&#xE1;ria da al&#xE7;a ileal no 10&#xBA; p&#xF3;s-operat&#xF3;rio, tendo resolu&#xE7;&#xE3;o a partir de medidas conservadoras. Sem outras intercorr&#xEA;ncias, recebeu alta hospitalar e seguiu em acompanhamento ambulatorial sem queixas, em programa de distens&#xE3;o da neobexiga (<xref ref-type="fig" rid="f2002">Figura 2</xref>). O anatomopatol&#xF3;gico revelou apenas cistite inflamat&#xF3;ria na pe&#xE7;a cir&#xFA;rgica e aus&#xEA;ncia de neoplasia.</p>
        <p>
<fig id="f1002" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Uretrocistografia. Bexiga de pequena capacidade, refluxo vesicureteral bilateral grau I e res&#xED;duo p&#xF3;s-miccional</title></caption><graphic xlink:href="1679-4508-eins-12-4-0502-gf01-pt"/></fig>
</p>
        <p>
<fig id="f2002" orientation="portrait" position="float"><label>Figura 2</label><caption><title>Uretrocistografia. Neobexiga em p&#xF3;s-operat&#xF3;rio tardio</title></caption><graphic xlink:href="1679-4508-eins-12-4-0502-gf02-pt"/></fig>
</p>
      </sec>
      <sec>
        <title>DISCUSS&#xC3;O</title>
        <p>O uso da BCG &#xE9; considerado de escolha para carcinoma urotelial Ta/T1 de alto grau e carcinoma <italic>in situ</italic> ap&#xF3;s RTU, em particular a terapia de manuten&#xE7;&#xE3;o, a qual demonstrou ser superior &#xE0; quimioterapia intravesical, no que diz respeito ao retardo da progress&#xE3;o tumoral.<sup>(<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>)</sup> Entretanto, n&#xE3;o deve ser administrada imediatamente ap&#xF3;s a ressec&#xE7;&#xE3;o, esperando-se, em geral, 2 semanas para a cicatriza&#xE7;&#xE3;o local e evitando-se, assim, a absor&#xE7;&#xE3;o e a dissemina&#xE7;&#xE3;o hematog&#xEA;nica das micobact&#xE9;rias.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
        <p>Embora n&#xE3;o seja consenso a dose ideal, seis a oito instila&#xE7;&#xF5;es, uma vez por semana, seguidas por tr&#xEA;s doses de manuten&#xE7;&#xE3;o a cada 3/6 meses, no primeiro ano, e a cada 6 meses a partir do segundo ano, demonstraram resultados promissores, conforme o protocolo do estudo SWOG, o qual foi utilizado no caso em quest&#xE3;o.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
        <p>Assumindo-se que a terapia de manuten&#xE7;&#xE3;o &#xE9; necess&#xE1;ria para efic&#xE1;cia &#xF3;tima, a quest&#xE3;o da toxicidade torna-se mais relevante.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> Esta &#xE9; substancialmente maior com um tratamento intensivo, mas os efeitos secund&#xE1;rios graves t&#xEA;m sido tamb&#xE9;m observados depois de poucas instila&#xE7;&#xF5;es.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> Sintomas de armazenamento (dis&#xFA;ria, polaci&#xFA;ria e hemat&#xFA;ria) s&#xE3;o efeitos colaterais comumente associados, ocorrendo geralmente ap&#xF3;s a terceira aplica&#xE7;&#xE3;o; trata-se de uma consequ&#xEA;ncia da estimula&#xE7;&#xE3;o imunit&#xE1;ria, com libera&#xE7;&#xE3;o de linfocinas como uma resposta inflamat&#xF3;ria associada.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
        <p>O retardo de novas instila&#xE7;&#xF5;es de BCG ap&#xF3;s v&#xE1;rias RTU e o in&#xED;cio de antibi&#xF3;ticos antituberculose &#xE9; recomendado, pois podem ser &#xFA;teis se inflama&#xE7;&#xE3;o cont&#xED;nua ou infec&#xE7;&#xE3;o est&#xE3;o presentes.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
        <p>A bexiga contra&#xED;da, complica&#xE7;&#xE3;o incomum, por&#xE9;m uma das mais graves, ocorre em menos de 1% dos doentes.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> Uma s&#xE9;rie atualizada por Lamm et al. relatou bexigas contra&#xED;das em apenas 5 pacientes (0,2%) de 2.602 analisados.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup>
</p>
        <p>No trabalho de Nieder et al., foram identificados apenas dois casos dessa complica&#xE7;&#xE3;o num total de 2.255 em duas institui&#xE7;&#xF5;es, numa taxa de 0,05 a 0,3%. Neste estudo, ambos os casos apresentaram complica&#xE7;&#xE3;o da terapia intravesical ainda no esquema de indu&#xE7;&#xE3;o, inclusive um deles com evid&#xEA;ncia de bexiga contra&#xED;da ap&#xF3;s a quinta dose. Possivelmente, h&#xE1; extravasamento em um local de ressec&#xE7;&#xE3;o n&#xE3;o cicatrizado, que iniciaria uma inflama&#xE7;&#xE3;o extensa perivesical e um trajeto fistuloso, resultando na bexiga contra&#xED;da.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup>
</p>
        <p>Devido a isso, tal complica&#xE7;&#xE3;o deve ser suspeitada em pacientes com sintomas miccionais intensos em qualquer fase e, principalmente, na manuten&#xE7;&#xE3;o da imunoterapia com BCG.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>)</sup> Atualmente, alguns centros utilizam isoniazida profil&#xE1;tica na tentativa de diminuir sua incid&#xEA;ncia, por&#xE9;m com resultados vari&#xE1;veis.<sup>(<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup> O uso de interferon associado foi proposto tamb&#xE9;m na tentativa de diminuir a dose e a intoler&#xE2;ncia da BCG, com algumas s&#xE9;ries de poucos pacientes apresentando resultados favor&#xE1;veis. No estudo aqui citado foi descrito o primeiro caso de bexiga contra&#xED;da em paciente na vig&#xEA;ncia dessa terapia combinada.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> O tratamento inicial pode ser tentado com medidas conservadoras, como hidrodistens&#xE3;o e uso de antimuscar&#xED;nicos.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup> Entretanto, naqueles refrat&#xE1;rios ou com sintomas incapacitantes, a indica&#xE7;&#xE3;o cir&#xFA;rgica deve ser considerada. Op&#xE7;&#xF5;es como amplia&#xE7;&#xE3;o vesical e cistectomia com reconstru&#xE7;&#xE3;o de conduto ileal poderiam levar ao risco de recidiva tumoral futura e a efeitos negativos na qualidade de vida (QV), respectivamente.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> J&#xE1; a cistoprostatectomia com reconstru&#xE7;&#xE3;o de neobexiga intestinal tem seu papel com melhora da QV e seguran&#xE7;a quanto a poss&#xED;veis recidivas tumorais.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup>
</p>
      </sec>
      <sec>
        <title>CONCLUS&#xC3;O</title>
        <p>A bexiga contra&#xED;da &#xE9; uma complica&#xE7;&#xE3;o rara mas que deve ser lembrada em pacientes com sintomas do trato urin&#xE1;rio inferior grave em vig&#xEA;ncia da terapia com bacilo de Calmette-Gu&#xE9;rin. Na intratabilidade cl&#xED;nica, a corre&#xE7;&#xE3;o cir&#xFA;rgica com cistoprostatectomia e neobexiga parece ser a melhor op&#xE7;&#xE3;o, devido ao seu tratamento definitivo e &#xE0; melhora na qualidade de vida.</p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
